Klinická hodnocení moderních léčiv vedou k úsporám ve zdravotnictví ve výši až 3,5 mld. Kč
| Title in English | Clinical evaluations of modern medicines lead to savings in the healthcare sector of up to 3.5 billion CZK |
|---|---|
| Authors | |
| Year of publication | 2022 |
| MU Faculty or unit | |
| Citation | |
| Description | Based on the press conference on May 24, 2022, in Prague on the occasion of the 5th National Day of Clinical Trials, České noviny published an article about clinical studies and CZECRIN. What impact do clinical trials have on health system savings? How do we compare to other countries in clinical research? Read the article or play the recording of the press conference. The CZECRIN research infrastructure, the IBD Patients Association, and the Innovative Pharmaceutical Industry Association participated. The research of new drugs, the so-called clinical trials (CT), is a prestigious, complicated process taking place worldwide, including in the Czech Republic. Today, clinical trials in the Czech Republic are pretty fragmented - each medical facility has different rules and instructions, and the administrative burden is enormous. This often slows down the start of studies, which is problematic concerning the worldwide conduct of studies. Therefore, pharmaceutical companies sometimes turn to researchers from other countries, where the implementation of studies is less complicated. |
| Related projects: |